Trial Profile
Pulmonary Rehabilitation in COPD: Response to Inhaled Treprostinil (Tyvaso)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary) ; Salbutamol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 12 Jun 2020 Status changed from recruiting to discontinued as trial unable to enrol.
- 15 Aug 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
- 15 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2020.